{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:44Z","timestamp":1785822464844,"version":"3.56.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the clinical efficacy, safety, and pharmacoeconomic value of aprepitant injection versus aprepitant capsules in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy, and to provide evidence for optimizing antiemetic strategies and rational healthcare resource allocation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This real-world observational study retrospectively included patients with solid tumors who received moderately to highly emetogenic chemotherapy regimens in our hospital from January 2023 to December 2025. Among 368 eligible patients, 62 received aprepitant capsules and 306 received aprepitant injection as part of a. Standard triple antiemetic regimen (NK- one receptor antagonist + 5-HT3 receptor antagonist + dexamethasone). After 1:1 propensity score matching (PSM), 60 matched pairs were included for comparative analysis. Clinical efficacy outcomes included complete response (CR), no nausea rate (NCR), no vomiting rate (NVR), and no rescue treatment rate (NRR) during the overall (0\u2013120\u00a0h), acute (0\u201324\u00a0h), and delayed (24\u2013120\u00a0h) phases. Quality of life was assessed using the EORTC QLQ-C30 questionnaire. Safety indicators included treatment-related adverse events. Pharmacoeconomic evaluation was conducted from the healthcare system perspective, incorporating antiemetic drug costs, total medication costs (antiemetics, chemotherapy drugs, adjuvant drugs), examination fees, laboratory costs, treatment fees, and total hospitalization costs. Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), incremental cost-effectiveness ratio (ICER), incremental cost-utility ratio (ICUR), Monte Carlo simulation, and cost-effectiveness acceptability curves (CEAC) were applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM, baseline characteristics between groups were well balanced (P &amp;gt; 0.05). The overall complete response rates were 78.3% in the injection group and 76.7% in the capsule group, with no statistically significant difference (P &amp;gt; 0.05). Acute and delayed phase CR rates, NCR, NVR, and NRR were also comparable between groups (all P &amp;gt; 0.05). Both groups showed significant post-chemotherapy improvements in EORTC QLQ-C30 functional and global health scores, with reduced symptom burden (P &amp;lt; 0.05), while intergroup differences remained non-significant (P &amp;gt; 0.05). The average antiemetic drug cost was significantly lower in the injection group than in the capsule group due to lower acquisition costs. The mean total hospitalization cost was lower in the injection group than in the capsule group (12,856.42 vs. 13,968.57 RMB), corresponding to an incremental cost difference of \u22121,112.15 RMB. Cost-effectiveness analysis yielded an incremental cost-effectiveness ratio of \u221266,996.99 RMB per additional complete response achieved, indicating lower costs with slightly improved effectiveness. Cost-utility analysis yielded an incremental cost-utility ratio of \u2212111,215.00 RMB per unit improvement in global health status score. Monte Carlo simulation and CEAC confirmed the robustness of the pharmacoeconomic advantage of aprepitant injection across a wide range of willingness-to-pay thresholds. Safety profiles were comparable, with no significant differences in adverse event incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Aprepitant injection and aprepitant capsules showed no statistically significant differences in efficacy, safety, or quality-of-life outcomes in this matched retrospective cohort. However, aprepitant injection demonstrated superior pharmacoeconomic performance through lower antiemetic drug costs, reduced total hospitalization expenditures, and more favorable economic outcomes. From a healthcare resource utilization perspective, aprepitant injection may represent a more cost-effective prophylactic antiemetic strategy and could provide useful evidence for individualized clinical decision-making and reimbursement policy optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1879202","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:39:33Z","timestamp":1785821973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A pharmacoeconomic evaluation of aprepitant injection versus aprepitant capsules for the prevention of CINV caused by moderately and highly emetogenic chemotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhen","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Hefei","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Anhui University of Chinese Medicine","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Hefei","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Hefei","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Hefei","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Third People\u2019s Hospital of Hefei","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Hefei","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s12325-023-02474-5","article-title":"Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting: a short review and clinical perspective","volume":"40","author":"Abe","year":"2023","journal-title":"Adv. Ther."},{"key":"B2","article-title":"CADTH health technology review","volume-title":"Aprepitant for the Prevention of Post-operative Nausea and Vomiting in Refractory or High-Risk Patients: Rapid Review. 2022, Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 2022 Canadian Agency for Drugs and Technologies in Health","author":"Authors","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"104444","DOI":"10.1016\/j.critrevonc.2024.104444","article-title":"Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: the road to success","volume":"201","author":"Belluomini","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/14740338.2020.1724955","article-title":"A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches","volume":"19","author":"Bossi","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/14656566.2023.2201372","article-title":"Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer","volume":"24","author":"Boscolo Bielo","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00520-025-09211-4","article-title":"MASCC antiemetic consensus recommendations: resource-limited settings","volume":"33","author":"Bosnjak","year":"2025","journal-title":"Support Care Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14737167.2021.1882306","article-title":"Pharmacoeconomics of obesity in China: a scoping review","volume":"21","author":"Chen","year":"2021","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-023-07978-y","article-title":"Prevalence and predictors of long-delayed (> 120 H) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis","volume":"31","author":"Chow","year":"2023","journal-title":"Support Care Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.1007\/s00520-022-07082-7","article-title":"A real-world study to evaluate the safety and eficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients","volume":"30","author":"Dranitsaris","year":"2022","journal-title":"Support Care Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.ctrv.2023.102512","article-title":"Eficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis","volume":"115","author":"Filetti","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12885-023-11070-3","article-title":"Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy","volume":"23","author":"Gao","year":"2023","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1200\/JCO.19.00470","article-title":"Palliative care and the management of common distressing symptoms in advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue","volume":"38","author":"Henson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/jdi.14265","article-title":"Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: japanese real-world data","volume":"15","author":"Horii","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"B16","first-page":"417","article-title":"Evaluation and treatment of nausea and vomiting in adults","volume":"109","author":"Johns","year":"2024","journal-title":"Am. Fam. Physician"},{"key":"B17","doi-asserted-by":"publisher","first-page":"115451","DOI":"10.1016\/j.ejca.2025.115451","article-title":"Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"222","author":"Jordan","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CE.S203634","article-title":"Management of chemotherapy-induced nausea and vomiting (CINV): a short review on the role of Netupitant-Palonosetron (NEPA)","volume":"15","author":"Lorusso","year":"2020","journal-title":"Core Evid."},{"key":"B19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11864-020-0702-x","article-title":"How E fective is palliative care in improving patient outcomes?","volume":"21","author":"Milazzo","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e70549","DOI":"10.1002\/cam4.70549","article-title":"NEPA (Netupitant\/Palonosetron) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy who experienced breakthrough CINV in cycle 1 of chemotherapy: a phase II clinical trial","volume":"14","author":"Navari","year":"2025","journal-title":"Cancer Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/oncolo\/oyac240","article-title":"Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles","volume":"28","author":"Navari","year":"2023","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1007\/s10147-025-02894-z","article-title":"Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy","volume":"30","author":"Okuyama","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1007\/s00520-022-07287-w","article-title":"Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis","volume":"30","author":"Patel","year":"2022","journal-title":"Support Care Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00520-023-08119-1","article-title":"Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis","volume":"31","author":"Schwartzberg","year":"2023","journal-title":"Support Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11864-022-01045-0","article-title":"Management of fatigue in patients with advanced cancer","volume":"24","author":"Stone","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.euroneuro.2024.03.003","article-title":"Eficacy, acceptability and side-efects of oral versus long-acting- injectables antipsychotics: systematic review and network meta-analysis","volume":"83","author":"Wang","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.2147\/CMAR.S254398","article-title":"Eficacy of olanzapine-triple antiemetic regimen in patients with gastrointestinal tumor and high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: a retrospective study","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"818839","DOI":"10.3389\/fonc.2021.818839","article-title":"Eficacy and safety of thalidomide as a pre-medication of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC): a systematic review and meta-analysis","volume":"11","author":"Xie","year":"2021","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s11695-024-07338-7","article-title":"The E ficacy of aprepitant in preventing post-bariatric surgery nausea and vomiting: evidence from clinical trials","volume":"34","author":"Zhu","year":"2024","journal-title":"Obes. Surg."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1879202\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:39:35Z","timestamp":1785821975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1879202\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":30,"alternative-id":["10.3389\/fphar.2026.1879202"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1879202","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1879202"}}